Management of immune checkpoint therapy for patients with cancer in the face of COVID-19

The COVID-19 outbreak caused by SARS-CoV-2 challenges the medical system by interfering with routine therapies for many patients with chronic diseases. In patients with cancer receiving immune checkpoint inhibitors (ICIs), difficulties also arise from the incomplete understanding of the intricate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Chen, Li, Qianru, Wei, Yongchang, Li, Yuting, Li, Jun, Tao, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733227/
https://www.ncbi.nlm.nih.gov/pubmed/33303577
http://dx.doi.org/10.1136/jitc-2020-001593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733227/
https://www.ncbi.nlm.nih.gov/pubmed/33303577
http://dx.doi.org/10.1136/jitc-2020-001593

Ejemplares similares